BP Clenbuterol 40 mcg is a research-grade β2-adrenergic agonist reference compound supplied in 40 microgram oral units for in vitro receptor binding, lipolysis modelling, and rodent thermogenesis protocols conducted under South African Animal Ethics Committee oversight aligned with SANS 10386:2021. Its utility in these applications comes from selective β2 receptor engagement, which lets researchers isolate adrenergic signalling from confounding β1 and β3 pathways. Clenbuterol is regulated as a Schedule 4 prescription substance under the Medicines and Related Substances Act administered by SAHPRA, so any supply for laboratory work must remain strictly non-human and protocol-bound.
For South African researchers sourcing clenbuterol 40 mcg domestically without importing from EU or US catalogues, the relevant verification points are batch-specific HPLC purity on the Certificate of Analysis, documented receptor selectivity at the β2 subtype, and format clarity (oral tablet versus aqueous injectable). A 2024 Cureus review by Okechukwu et al. confirms clenbuterol's continued use as a mechanistic reference for β2-mediated metabolic-rate elevation, even as newer rodent studies shift toward formoterol. That persistence comes down to established dose-response characterisation and the cost of validating alternative reference standards.
Key Takeaways
- BP Clenbuterol 40 mcg is a Schedule 4 research-grade reference standard for β2-receptor studies in thermogenesis, lipolysis, and bronchodilation assays.
- Selectivity for β2 over β1 and β3 receptors allows isolation of adrenergic signalling pathways in cell culture and animal models.
- Aqueous injectable format suits in vitro dose-response work; oral tablets are practical for rodent gavage and chronic-exposure protocols.
- Research-grade material must meet ≥98% HPLC purity and be accompanied by a batch-specific Certificate of Analysis.
- All in vivo work requires ethics clearance under SANS 10386:2021 and must comply with SAHPRA scheduling restrictions.
- Clenbuterol is commonly paired with GH-axis modulators (CJC-1295, Ipamorelin) to compare adrenergic and somatotropic lipolytic pathways.
What Is BP Clenbuterol 40 mcg?
BP Clenbuterol 40 mcg is a research-grade reference standard of clenbuterol hydrochloride, a selective long-acting β2-adrenergic agonist, supplied in 40 microgram oral units by BodyPharm (BP) for in vitro and animal-model laboratory work only, not for human consumption. The compound carries the molecular formula C12H18Cl2N2O with a molecular weight of 277.19 g/mol and a notably prolonged plasma half-life of approximately 35–40 hours in mammalian models. That extended half-life makes it a useful sustained β2-receptor activation probe and distinguishes it from short-acting β2-agonists, making it suitable for chronic-exposure protocols where sustained receptor occupancy is the experimental goal.
BodyPharm classifies this material as research-grade rather than pharmaceutical-grade. Batch release relies on a Certificate of Analysis covering HPLC purity, assay, and impurity profile, but not on full GMP pharmacopoeial dossier compliance. Within South African research workflows, the unit is handled as a Schedule 4 substance under the Medicines and Related Substances Act and supplied strictly under protocol-bound, non-human terms.
For the broader compound family, see our clenbuterol research compounds parent listing, or compare adjacent metabolic-axis tools such as the CJC-1295 research peptide entry.
Beta-2 Receptor Mechanism in Thermogenesis Studies
Clenbuterol drives thermogenesis through selective β2-adrenergic receptor agonism. This activation triggers the Gs-coupled adenylyl cyclase → cAMP → PKA (protein kinase A) cascade. PKA then phosphorylates hormone-sensitive lipase (HSL) and perilipin, releasing free fatty acids from adipocyte lipid droplets.
That phosphorylation event is the mechanistic lynchpin. Unphosphorylated perilipin coats the lipid droplet and blocks lipase access. PKA-mediated phosphorylation removes this barrier and permits triglyceride hydrolysis. The same cAMP/PKA axis upregulates uncoupling protein-1 (UCP-1) in brown adipose tissue in rodent models. UCP-1 dissipates the mitochondrial proton gradient as heat rather than ATP, producing the measurable rise in resting metabolic rate that defines a thermogenic readout.
Receptor selectivity and protocol design
Clenbuterol's value as a probe lies in its β2:β1 selectivity, which is substantially higher than that of the non-selective reference agonist isoprenaline. Isoprenaline activates β1, β2, and β3 receptors indiscriminately. Clenbuterol biases signal toward β2 populations on white and brown adipocytes and skeletal myocytes, isolating β2-mediated lipolysis and UCP-1 induction from confounding β1 cardiac and β3 brown-fat-specific signal in the same preparation.
For in vitro 3T3-L1 differentiation assays or ex vivo brown adipose tissue (BAT) explants, this selectivity profile lets researchers attribute observed cAMP, glycerol release, or UCP-1 mRNA changes to β2 engagement with reasonable confidence. Non-selective agonists activate multiple receptor subtypes simultaneously and obscure which pathway drives the observed effect.
Mechanistic literature and protocol justification
The canonical β2-agonist thermogenesis dose-response work by Arch and colleagues in the International Journal of Obesity dates to 2002. Researchers building 2026 protocols should treat it as foundational rather than current. No 2024–2026 systematic review of β2-agonist thermogenesis in rodents specifically anchored on clenbuterol could be located in the indexed literature. Recent reviews such as the 2024 Cureus synthesis recapitulate the cAMP/PKA/HSL/UCP-1 pathway without contributing new in vitro data.
Protocol justifications should pair the older mechanistic data with a current database search before submission to an Animal Ethics Committee. This ensures the foundational mechanism is cited accurately while acknowledging that recent primary data on clenbuterol specifically are sparse.
For adjacent metabolic-axis probes, see the clenbuterol research compounds category and the CJC-1295 research peptide entry.
Lipolysis Research: What the Data Shows
Clenbuterol drives glycerol release in rodent adipocyte preparations through β2-mediated cAMP/PKA activation of hormone-sensitive lipase. Measurable effects occur in the nanomolar-to-low-micromolar range in vitro and microgram-per-kilogram dose-response curves in rodent models. The 2024 Cureus synthesis by Okechukwu et al. confirms that β2 engagement on white adipocytes translates to lipase phosphorylation and triglyceride hydrolysis. The review is narrative rather than presenting new primary data. This consistency across decades of literature suggests the mechanism is robust, but the absence of recent primary data means researchers cannot assume that newly synthesised β2-agonists will replicate clenbuterol's potency without direct testing.
Most lipolysis assays use glycerol release into the culture supernatant as the proxy marker. Glycerol is not re-esterified by adipocytes and accumulates stoichiometrically with triglyceride breakdown. Free fatty acid release is sometimes co-measured but is confounded by reuptake and intracellular re-esterification, making glycerol the cleaner readout for screening β2-agonist potency. Glycerol quantification via enzymatic assay (glycerol kinase coupled to a colourimetric or fluorometric readout) is standard and compatible with 96-well formats.
Use as a positive control
In β2-agonist screening panels, clenbuterol is commonly run as a positive control alongside isoprenaline (non-selective β-agonist) and a vehicle blank. EC50 values for glycerol release are used to rank candidate compounds. This three-arm design isolates β2-specific signal from β1/β3 contributions and from baseline lipolytic tone in differentiated 3T3-L1 or primary epididymal adipocyte cultures. The positive control arm establishes the assay's dynamic range and confirms that the cell preparation is responsive to β-agonism on the day of the experiment.
Extrapolation from rodent adipocyte EC50 values to human metabolic outcomes falls outside the scope of research-chemical use and is not supported by the in vitro data alone. Protocols should confine claims to the cellular or organ-level endpoints actually measured. Researchers building broader metabolic-axis panels alongside β2-agonist work may reference the clenbuterol research compounds category and adjacent GH-axis probes such as CJC-1295 for comparator design.
Bronchodilation Models: Secondary Research Applications
Clenbuterol is a long-acting β2-agonist used as a reference bronchodilator in airway smooth-muscle research. It produces documented relaxation of tracheal and bronchial preparations via cAMP-mediated myosin light-chain kinase inhibition. In airway smooth muscle, β2 receptor occupancy elevates intracellular cAMP through Gs-coupled adenylyl cyclase activation, driving PKA-mediated phosphorylation that reduces calcium sensitivity and produces sustained relaxation. This mechanism parallels the lipolytic pathway but operates in a different tissue context: the functional outcome is muscle relaxation rather than lipid mobilisation.
The pharmacokinetic profile distinguishes clenbuterol from short-acting β2-agonists such as salbutamol. Salbutamol's plasma half-life sits near 4–6 hours. Clenbuterol's reported half-life of approximately 26–36 hours allows single-dose sustained-exposure protocols in rodent and equine respiratory models without the repeated dosing cycles required for short-acting beta-agonists (SABAs). The extended half-life reduces dosing frequency and associated handling stress in animal protocols, making it a practical reference compound when chronic β2 stimulation, receptor desensitisation kinetics, or long-window tracheal contractility studies are the experimental endpoint.
Equine and rodent respiratory models
Equine recurrent airway obstruction (RAO) protocols have historically used clenbuterol as the standard bronchodilator comparator, given its registration for veterinary respiratory indications in several jurisdictions and its measurable effect on pulmonary resistance in horses. Rodent tracheal ring assays apply it similarly as a positive control alongside isoprenaline. Both model systems rely on clenbuterol's established potency and long half-life to produce sustained bronchodilation measurable over hours to days.
Airway applications remain secondary to the metabolic and lipolysis endpoints that dominate current research use. Teams building broader β2-agonist panels can cross-reference the clenbuterol research compounds category when designing comparator arms.
Oral vs. Aqueous Injectable Format: Research Comparison
Aqueous injectable clenbuterol HCl is the preferred format for cell-culture and direct-injection protocols. The 40 mcg oral tablet is the practical choice for rodent gavage and chronic-exposure animal studies. The selection hinges on excipient interference, titration resolution, and the route demanded by the model.
Clenbuterol hydrochloride is freely water-soluble (approximately 100 mg/mL), which removes the need for DMSO or ethanol carriers in aqueous preparations. This eliminates a common confounder in β2 receptor signalling assays where solvent vehicles independently affect cAMP readouts. Tablet excipients (microcrystalline cellulose, magnesium stearate, lactose binders) are inert in vivo but can suppress MTT/resazurin signals and skew cell-viability endpoints in 96-well formats. Tablets are not appropriate for in vitro cytotoxicity work without prior extraction and filtration, vehicle effects can rival or exceed the compound's own signal in sensitive assays.
Dosing resolution differs sharply. A 40 mcg oral tablet is a fixed unit; sub-40 mcg titration requires dissolution and serial dilution, which introduces pipetting variance. Aqueous injectable stock supports nanogram-range titration directly from a known mg/mL concentration. This matters when constructing dose-response curves across three log units for EC50 determination on β2 adrenergic receptor models. Continuous titration rather than fixed steps is essential for accurate potency ranking.
Stability and storage
Both formats hold assay-grade integrity at −20 °C for the periods typical of multi-week protocols. Oral tablets tolerate short-term room-temperature handling better than reconstituted aqueous solutions, which should be aliquoted to avoid freeze-thaw degradation. For chronic rodent gavage paradigms (for example, 14–28 day thermogenesis exposures), the tablet format simplifies logistics. For acute intraperitoneal or subcutaneous dosing, the aqueous injectable removes a dissolution step. The choice comes down to whether the priority is ease of animal handling or precision of in vitro titration.
| Parameter | Oral Tablet (40 mcg) | Aqueous Injectable |
|---|---|---|
| Solvent system | Solid; requires dissolution | Pre-solubilised in aqueous vehicle |
| Titration resolution | Fixed 40 mcg unit | Continuous (mg/mL stock) |
| In vitro suitability | Limited (excipient interference) | Direct addition to media |
| Rodent gavage | Preferred | Possible but unnecessary |
| Acute IP/SC dosing | Requires reconstitution | Preferred |
| Room-temperature stability (short term) | Higher | Lower (aliquot and freeze) |
| −20 °C long-term storage | Stable | Stable |
Researchers building parallel arms across the clenbuterol research compounds catalogue or pairing β2-agonist exposure with GH-axis modulators such as CJC-1295 should match format to assay endpoint rather than defaulting to whichever stock is on hand.
Research-Grade Quality Standards for Clenbuterol
Research-grade clenbuterol is material certified to a minimum of ≥98% HPLC purity with a batch-specific Certificate of Analysis. It is intended for laboratory use only and is distinct from pharmaceutical-grade product manufactured under GMP for human dispensing. Pharmaceutical-grade tablets carry excipients optimised for oral bioavailability; research-grade reference material is characterised for assay reproducibility and impurity profiling. That difference in manufacturing intent translates to different quality assurance priorities: pharmaceutical-grade focuses on bioavailability and shelf-life under consumer conditions, whereas research-grade prioritises analytical purity and batch-to-batch consistency.
For publishable in vitro work, ≥98% HPLC purity is the accepted floor, aligning with ICH Q6A specifications for new chemical substances used in analytical and pharmacological characterisation. Below that threshold, isomeric or synthesis-related impurities can confound β2 adrenergic receptor binding curves and inflate apparent EC50 values across replicate plates. A 1% impurity may seem trivial, but in a dose-response assay spanning three log units it introduces systematic error that can shift EC50 estimates by 0.1 to 0.3 log units.
A usable Certificate of Analysis states the batch number, assay percentage, HPLC method (column, mobile phase, detection wavelength), and impurity profile. Before committing material to a study, I recommend independent mass spectrometry confirmation of the 277.0 g/mol molecular ion to verify identity, particularly when sourcing from a new lot. This two-step verification (vendor CoA plus in-house MS) is standard practice when building dose-response data intended for peer review. The MS confirmation takes one to two hours and costs approximately R800–R1,500 at most South African contract analytical laboratories, a modest outlay relative to the cost of a failed study.
Why purity drives reproducibility
A 1% shift in active content propagates linearly through serial dilutions. A 97% lot tested against a 99% lot will produce systematically displaced curves. Researchers running parallel arms across clenbuterol research compounds or pairing β2 exposure with GH-axis tools such as CJC-1295 should hold a single batch for the duration of a study where feasible. If a batch change is unavoidable, validate the new batch against the old via a bridging dose-response curve before proceeding with the main experiment.
SAHPRA Regulatory Context in South Africa (2026)
Clenbuterol is regulated as a Schedule 4 substance under the schedules to the Medicines and Related Substances Act 101 of 1965 (as amended), administered by SAHPRA, and is not registered for human therapeutic use in South Africa as of 2026. Researchers procuring material for in vitro or animal-model work should treat the SAHPRA register (sahpra.org.za) as the authoritative reference for current scheduling status. Down-scheduling or research-exemption notices would appear there before any third-party summary. The register is updated quarterly.
Research-grade reference material supplied for laboratory characterisation, receptor binding assays, and analytical method development occupies a distinct supply context from finished-dose medicines intended for human dispensing, but it does not exit the Schedule 4 framework. Suppliers and purchasers must not market, label, or distribute the compound for human consumption, and procurement records should reflect laboratory end-use. Failure to maintain this distinction exposes both supplier and purchaser to regulatory action under the Medicines and Related Substances Act.
For animal protocols, SANS 10386:2021 governs the care and use of animals for scientific purposes. Institutional Animal Ethics Committees, NSPCA oversight, and SAVC professional standards expect any β2-agonist administration to be scientifically justified, veterinarian-supervised, and aligned with the 3Rs (replacement, reduction, refinement). Ethics clearance under the National Health Act 61 of 2003 framework remains a prerequisite for any in vivo work involving clenbuterol research compounds or adjacent GH-axis tools such as CJC-1295. This section is not legal advice; consult your institutional research office and ethics committee for binding determinations.
How BP Clenbuterol 40 Fits Into a Metabolic Research Stack
In metabolic phenotyping work, clenbuterol most often serves as a β2-adrenergic lipolysis positive control against which peptide-driven mechanisms are benchmarked. Research protocols comparing adrenergic versus somatotropic lipolytic pathways frequently run clenbuterol research compounds in parallel arms with GH-axis modulators such as CJC-1295, Ipamorelin, or Tesamorelin. The question is whether downstream IGF-1 (insulin-like growth factor 1) elevation produces comparable adipocyte triglyceride mobilisation to direct β2 stimulation. This comparison design isolates the lipolytic contribution of each pathway and reveals whether GH-axis activation converges on the same effector molecules (HSL, perilipin) as β2 agonism.
GLP-1 (glucagon-like peptide-1) receptor agonist arms (Tirzepatide, Semaglutide) are increasingly added to the same phenotyping matrices to dissociate central appetite-mediated effects from peripheral lipolytic signalling. AOD-9604 and IGF-1 LR3 appear in adipocyte and myocyte assays for similar reference-compound reasons. None of this implies co-administration in a single subject: each compound entering an in vivo South African protocol requires its own scientific justification, dose rationale, and Animal Ethics Committee clearance under SANS 10386:2021. Combination arms trigger additional ethics review rather than a single blanket approval, and the committee will expect to see the mechanistic rationale for each arm alongside evidence that the combination does not introduce unexpected toxicity or off-target effects.
Ordering BP Clenbuterol 40 mcg in South Africa
BP Clenbuterol 40 mcg is stocked by JCSG.org for laboratory research use only and is dispatched domestically via discreet, tracked courier with secure checkout in ZAR. Pricing is listed on the product page within the clenbuterol research compounds category; check the product page directly rather than relying on third-party quotes. A batch-specific Certificate of Analysis covering HPLC purity, assay, and impurity profile is available on request from the QA team and should be reviewed before any in vitro work begins.
Orders are supplied strictly for in vitro and ethics-cleared in vivo protocols. Clenbuterol remains a Schedule 4 substance under the Medicines and Related Substances Act administered by SAHPRA and must not be diverted to clinical or athletic use. Researchers benchmarking adrenergic against somatotropic lipolysis can pair the order with a CJC-1295 research peptide reference arm in the same checkout.
Frequently Asked Questions
What HPLC purity is BP Clenbuterol 40 mcg supplied at?
Each batch ships with a Certificate of Analysis covering HPLC purity, assay, and impurity profile. JCSG.org's QA team releases the CoA on request before dispatch, so the numeric purity figure should be read from the current batch document rather than a fixed catalogue claim.
Is clenbuterol legal to purchase in South Africa for research?
Clenbuterol is regulated as a Schedule 4 medicine under the Medicines and Related Substances Act administered by SAHPRA, which means it is prescription-controlled and not exempted for unrestricted research supply. Laboratory-only purchases must be tied to an ethics-cleared protocol, and the compound must not be diverted to human or athletic use.
What is the difference between oral and aqueous injectable clenbuterol for in vitro work?
For cell-culture and receptor-binding assays, the format question collapses to solubility and vehicle control: clenbuterol HCl dissolves readily in aqueous buffer or DMSO regardless of whether the source material is a tablet-format reference or an aqueous stock. Powder or crystalline HCl is generally preferred for in vitro work because it allows precise gravimetric weigh-out and avoids preservatives present in injectable formulations.
How should research-grade clenbuterol be stored?
Store the lyophilised or crystalline material at −20 °C for long-term stability and at 4 °C for short-term working stocks of up to one month. Protect from light and moisture, and aliquot reconstituted solutions to minimise freeze-thaw cycles.
Can clenbuterol be paired with peptide compounds in the same study?
Yes. Adrenergic-versus-somatotropic comparison arms are a common design, with CJC-1295 frequently run as a GH-axis reference alongside β2-agonists from the clenbuterol research compounds category, provided each arm has its own vehicle control and ethics approval.
Next Steps
Before ordering, confirm that your institution's Animal Ethics Committee or research office has reviewed your protocol and that your intended use aligns with SANS 10386:2021 and SAHPRA scheduling requirements. Request the batch-specific Certificate of Analysis from JCSG.org's QA team and verify HPLC purity and identity via independent mass spectrometry if your work will be submitted for peer review. Once material arrives, store it at −20 °C and aliquot working stocks to preserve stability across your study duration. If you are designing a multi-arm metabolic phenotyping study, pair your clenbuterol order with a CJC-1295 research peptide reference arm to isolate adrenergic and somatotropic lipolytic pathways.
